Cargando…
Development of the Drug Product Formulation of the Bevacizumab Biosimilar PF-06439535 (Bevacizumab-bvzr)
BACKGROUND: PF-06439535 (bevacizumab-bvzr; Zirabev(®)) is a biosimilar of bevacizumab reference product (RP; Avastin(®)). This study describes the formulation development for PF-06439535. METHODS: PF-06439535 was formulated in several buffers and stored for 12 weeks at 40 °C to determine the optimal...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985529/ https://www.ncbi.nlm.nih.gov/pubmed/36811761 http://dx.doi.org/10.1007/s40268-023-00411-z |